Compare ASPS & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASPS | LUNG |
|---|---|---|
| Founded | 1999 | 1995 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.9M | 63.6M |
| IPO Year | N/A | 2020 |
| Metric | ASPS | LUNG |
|---|---|---|
| Price | $7.06 | $2.23 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $6.81 |
| AVG Volume (30 Days) | 24.0K | ★ 827.0K |
| Earning Date | 10-23-2025 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | ★ $169,648,000.00 | $91,664,000.00 |
| Revenue This Year | $38.29 | $9.21 |
| Revenue Next Year | N/A | $5.03 |
| P/E Ratio | $1,046.65 | ★ N/A |
| Revenue Growth | 10.68 | ★ 15.59 |
| 52 Week Low | $4.92 | $1.31 |
| 52 Week High | $15.96 | $9.37 |
| Indicator | ASPS | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 43.35 | 51.54 |
| Support Level | $6.80 | $2.18 |
| Resistance Level | $7.53 | $2.39 |
| Average True Range (ATR) | 0.42 | 0.16 |
| MACD | 0.15 | -0.04 |
| Stochastic Oscillator | 59.13 | 15.31 |
Altisource Portfolio Solutions SA is an integrated service provider and marketplace for the real estate and mortgage industries. It operates via two reportable segments, namely Servicer and Real Estate, which derive maximum revenue, and Origination. The Servicer and Real Estate segment provides loan servicers and real estate investors with solutions and technologies that span the mortgage and real estate lifecycle. The Origination segment provides originators with solutions and technologies that span the mortgage origination lifecycle. Altisource mainly serves financial institutions, government-sponsored enterprises, and originators in the United States, with the majority of its revenue flowing from field services and mortgage and real estate solutions.
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.